rosiglitazone has been researched along with rotenone in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Althaym, A; Brunmair, B; Clara, R; Fürnsinn, C; Gnaiger, E; Gras, F; Nohl, H; Roden, M; Scharf, N; Staniek, K; Waldhäusl, W | 1 |
| Evangelinos, N; Kaloyianni, M; Koliakos, G; Koutsogiannaki, S | 1 |
| Brenton, J; Cordeiro, MF; Davis, BM; De Groef, L; Guo, L; Malaguarnera, G; Nizari, S; Normando, EM; Pahlitzsch, M; Ravindran, N; Somavarapu, S; Turner, LA | 1 |
7 other study(ies) available for rosiglitazone and rotenone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?
Topics: Animals; Electron Transport Complex I; Energy Metabolism; Hypoglycemic Agents; Male; Metformin; Mitochondria; Muscle, Skeletal; Oxygen Consumption; Pioglitazone; Potassium Chloride; Rats; Rats, Sprague-Dawley; Rosiglitazone; Rotenone; Thiazolidinediones | 2004 |
Cytotoxic mechanisms of Zn2+ and Cd2+ involve Na+/H+ exchanger (NHE) activation by ROS.
Topics: Acetylcysteine; Amiloride; Animals; Antimycin A; Antioxidants; Cadmium; Cadmium Poisoning; Cell Survival; Gills; Hydrogen-Ion Concentration; Mytilus; Naphthalenes; Oxidants; PPAR gamma; Protein Kinase Inhibitors; Pyruvic Acid; Reactive Oxygen Species; Receptors, Adrenergic; Rosiglitazone; Rotenone; Sodium-Hydrogen Exchangers; Thiazolidinediones; Water Pollutants, Chemical; Zinc | 2006 |
The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Topics: Animals; Antiparkinson Agents; Brain; Cell Survival; Cells, Cultured; Disease Progression; Drug Evaluation, Preclinical; Follow-Up Studies; Neuroprotective Agents; Parkinsonian Disorders; PPAR gamma; Rats; Retina; Rosiglitazone; Rotenone; Superior Sagittal Sinus; Thiazolidinediones; Tomography, Optical Coherence | 2016 |